PMDA-2022-0003-V403

Type IB variation for application PMDA-2022-0003. Type IB variation: Facility Change for Tiotropizone — major revision

Variation Number
PMDA-2022-0003-V403
Type
Type IB
Application
PMDA-2022-0003
Change
CHG-2022-0103
Status
Overdue
Fee
€4,398
Submitted
2023-09-04
Approved
—
Description

Type IB variation: Facility Change for Tiotropizone — major revision